Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 17;11(4):e006334. doi: 10.1136/jitc-2022-006334

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Verification of new hepatocellular carcinoma-dominant neoantigens by the Co-HA system. (A) The transcriptional neoantigen 5'-FYAFSCYYDL-3' verified in the tumor tissues of patient 04 with Sanger sequencing. (B) The specific secretion of IFN-γ by T cells from PBMCs of patient 04 against the neoantigen 5'-FYAFSCYYDL-3' in the Co-HA system detected by ELISpot. (C) The specific lysis of the COS-7 cells generated by the neoantigen 5'-FYAFSCYYDL-3' in the Co-HA system detected by Sanger sequencing. (D) The specific secretion of IFN-γ by T cells from PBMCs of patient 04 against the neoantigen 5'-FYAFSCYYDL-3' in the Co-HA system detected by ELISA. (E) The LDH levels induced by the specific T cells against the neoantigen 5'-FYAFSCYYDL-3' in the Co-HA system detected by ELISA. (F) The transcriptional neoantigen 5'-WVWCMSPTI-3' verified in the tumor tissues of patient 05 with Sanger sequencing. (G) The specific secretion of IFN-γ by T cells from PBMCs of patient 05 against the neoantigen 5'-WVWCMSPTI-3' in the Co-HA system detected by ELISpot. (H) The specific lysis of the COS-7 cells generated by the neoantigen 5'-WVWCMSPTI-3' in the Co-HA system detected by Sanger sequencing. (I) The specific secretion of IFN-γ by T cells from PBMCs of patient 05 against the neoantigen 5'-WVWCMSPTI-3' in the Co-HA system detected by ELISA. (J) The LDH levels induced by the specific T cells against the neoantigen 5’-WVWCMSPTI-3’ in the Co-HA system detected by ELISA. HLA, human leukocyte antigen; ELISpot, enzyme-linked immunospot assay; IFN-γ, interferon-γ; LDH, lactate dehydrogenase; PBMCs, peripheral blood mononuclear cells.